Narendra Pentu
Research Subjects
Narendra Pentu has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Ajitha Azhakesan
Department of Pharmaceutical Chemistry, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), Chennai – 600116, Tamil Nadu, India
4 shared publications Ashok Morsu
PPD part of Thermo Fischer Scientific, 3900 Paramount Parkway, Morrisville N.C. 27560
2 shared publicationsPasupuleti Kishore Kumar
Department of Pharmacology, CMR College of Pharmacy, Kandlakoya (V), Medchal, Hyderabad, Telangana-501401
2 shared publications- Tadikonda Rama Rao
CMR College of Pharmacy
2 shared publications - Uma Maheshwararao Vattikuti
Department of Pharmacognosy, CMR College of Pharmacy, Kandlakoya, Medchal, Hyderabad – 501401, Telangana, India
2 shared publications - V. V. Rajesham
Department of Pharmacology, CMR College of Pharmacy, Kandlakoya, Medchal, Hyderabad – 501401, Telangana, India
2 shared publications
Latest Publications
- 29 October 2026
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- Vol. 2026 (10) , 2785-2796
In Silico Pharmacokinetic Profiling and Molecular Docking Analysis of Centella asiatica for Anti-psoriatic Activity
Background: Rapid estimation of drug-related properties accelerates the drug discovery process. Integration of computational methods leverages the drug discovery pipeline. The early-stage detection of Absorption Distribution Metabolism Excretion Toxicity (ADMET) properties reduces the time and experimental costs. The study aimed to evaluate the ADMET properties (Pharmacokinetic properties were predicted using pkCSM) of 27 compounds present in the Centella asiatica plant against the inhibitory potential of proteins escalated in keratinocyte proliferation of psoriasis. Methods: Chemical structures were optimised, and ADMET properties- LogS, LogP, Caco2, Cytochrome P450 (CYP450), human Ether a-go-go Related Gene (hERG) inhibition, Lethal Dose 50% (LD50), and Maximum allowable dosage- were measured using SWISSADME and pkCSM web servers. Data analysis included Pearson correlation, Principal Component Analysis (PCA), and hierarchical clustering. Molecular docking simulation was performed using AutoDock Vina software (Discovery Studio). Results: Correlation analysis reveals the interrelationship between LogS and LogP, with clustering based on similar properties. Molecular docking studies reveal the favourable binding affinity of the drug molecules with the targeted proteins IL-17A, IL-23, and IL-6. Conclusion: Advanced computational tools and their reproducibility of drug-related properties are useful for the drug discovery process. The present approach enabled us to identify the potential natural compound with anti-psoriatic activity. Natural therapies are useful for long-term use, and they may produce fewer adverse effects. Major Findings: Computational ADMET profiling and docking revealed caffeoylquinic acids, flavonoids, and triterpenoids from Centella asiatica as promising antipsoriatic agents with strong binding to IL17A, IL23, and IL6. These natural compounds demonstrated favourable pharmacokinetic properties and inhibitory potential, supporting their use as safer longterm therapeutic candidates.
- 29 October 2026
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- Vol. 2026 (10) , 2785-2796
In Silico Pharmacokinetic Profiling and Molecular Docking Analysis of Centella asiatica for Anti-psoriatic Activity
Background: Rapid estimation of drug-related properties accelerates the drug discovery process. Integration of computational methods leverages the drug discovery pipeline. The early-stage detection of Absorption Distribution Metabolism Excretion Toxicity (ADMET) properties reduces the time and experimental costs. The study aimed to evaluate the ADMET properties (Pharmacokinetic properties were predicted using pkCSM) of 27 compounds present in the Centella asiatica plant against the inhibitory potential of proteins escalated in keratinocyte proliferation of psoriasis. Methods: Chemical structures were optimised, and ADMET properties- LogS, LogP, Caco2, Cytochrome P450 (CYP450), human Ether a-go-go Related Gene (hERG) inhibition, Lethal Dose 50% (LD50), and Maximum allowable dosage- were measured using SWISSADME and pkCSM web servers. Data analysis included Pearson correlation, Principal Component Analysis (PCA), and hierarchical clustering. Molecular docking simulation was performed using AutoDock Vina software (Discovery Studio). Results: Correlation analysis reveals the interrelationship between LogS and LogP, with clustering based on similar properties. Molecular docking studies reveal the favourable binding affinity of the drug molecules with the targeted proteins IL-17A, IL-23, and IL-6. Conclusion: Advanced computational tools and their reproducibility of drug-related properties are useful for the drug discovery process. The present approach enabled us to identify the potential natural compound with anti-psoriatic activity. Natural therapies are useful for long-term use, and they may produce fewer adverse effects. Major Findings: Computational ADMET profiling and docking revealed caffeoylquinic acids, flavonoids, and triterpenoids from Centella asiatica as promising antipsoriatic agents with strong binding to IL17A, IL23, and IL6. These natural compounds demonstrated favourable pharmacokinetic properties and inhibitory potential, supporting their use as safer longterm therapeutic candidates.
- Open Access
- 14 September 2026
- Published by Elsevier in SSRN Electronic Journal
Evaluation of Cinchonidine as a Dual Antioxidant and Acetylcholinesterase Modulator for the Amelioration of AlCl3-Induced Neurotoxicity against Alzheimer's Disease
BackgroundAlzheimer’s disease (AD) is a global health crisis marked by amyloid plaques, tau hyperphosphorylation, and oxidative stress. Cinchonidine, a quinoline alkaloid, is promising herbal medicine with therapeutic benefits as a natural alternative to conventional drugs. This study investigated the neuroprotective potential of Cinchonidine (CD), a cinchona alkaloid and stereoisomer of quinine, using in-silico, in-vitro antioxidant and by in-vivo activity against aluminium chloride-induced cognitive dysfunction in rats.MethodologyMolecular docking of cinchonidine and standard drugs (donepezil) targeting Alzheimer's disease-related proteins (Acetylcholinesterase, PDB: 6ZWE) was performed using AutoDock Vina. Proteins were prepared by removing water and ligands, with active sites predicted via GRID box blind docking. Ligands were sourced from PubChem and converted to PDB format. Docking results were analyzed for binding affinity and interactions using Discovery Studio. In-vitro antioxidant activity of cinchonidine was assessed through H2O2 scavenging, DPPH, and FRAP assays. In-vivo studies employed adult male Wistar rats (200–250 g), divided into six groups (control, AlCl3-induced Alzheimer’s model, three cinchonidine dose groups at 10, 20, and 40 mg/kg, and a donepezil standard group). Treatments were administered orally for 21 days. Cognitive and behavioural assessments included the Elevated Plus Maze, T-maze, Y-maze, and locomotor activity via actophotometer. Post-treatment, hippocampus and cortex homogenates were analysed for acetylcholinesterase activity (Ellman’s method), catalase, lipid peroxidation (MDA via TBARS), and superoxide dismutase activities using spectrophotometric assays.ResultsMolecular docking revealed that cinchonidine binds acetylcholinesterase (AChE) with a −8.3 kcal/mol affinity, forming key hydrogen bonds and hydrophobic interactions, albeit weaker than donepezil (−11.3 kcal/mol). In-vitro assays demonstrated cinchonidine’s dose-dependent antioxidant activity comparable to ascorbic acid across H₂O₂ scavenging, DPPH, and FRAP assays. In-vivo, cinchonidine dose-dependently ameliorated AlCl₃-induced cognitive deficits, anxiety-like behaviour, and locomotor impairments in rats, paralleling donepezil effects. Biochemically, cinchonidine significantly restored brain AChE, lipid peroxidation, catalase, superoxide dismutase, and reduced glutathione levels (p < 0.05-0.001), indicating neuroprotective antioxidant and cholinergic modulation relevant to Alzheimer’s therapy.ConclusionCinchonidine demonstrated significant neuroprotective effects against AlCl3-induced cognitive dysfunction in rats through acetylcholinesterase inhibition and potent antioxidant activity. In-silico, in-vitro, and in-vivo results consistently showed dose-dependent improvements in cognitive behaviour, cholinergic function, and oxidative stress markers, comparable to donepezil. These findings highlight cinchonidine’s potential as a multifunctional therapeutic candidate for Alzheimer’s disease. Further studies exploring molecular mechanisms, long-term safety, and pharmacokinetics are warranted to advance its clinical translation.
- 14 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessEvaluation of Cinchonidine as a Dual Antioxidant and Acetylcholinesterase Modulator for the Amelioration of AlCl3-Induced Neurotoxicity against Alzheimer's Disease
BackgroundAlzheimer’s disease (AD) is a global health crisis marked by amyloid plaques, tau hyperphosphorylation, and oxidative stress. Cinchonidine, a quinoline alkaloid, is promising herbal medicine with therapeutic benefits as a natural alternative to conventional drugs. This study investigated the neuroprotective potential of Cinchonidine (CD), a cinchona alkaloid and stereoisomer of quinine, using in-silico, in-vitro antioxidant and by in-vivo activity against aluminium chloride-induced cognitive dysfunction in rats.MethodologyMolecular docking of cinchonidine and standard drugs (donepezil) targeting Alzheimer's disease-related proteins (Acetylcholinesterase, PDB: 6ZWE) was performed using AutoDock Vina. Proteins were prepared by removing water and ligands, with active sites predicted via GRID box blind docking. Ligands were sourced from PubChem and converted to PDB format. Docking results were analyzed for binding affinity and interactions using Discovery Studio. In-vitro antioxidant activity of cinchonidine was assessed through H2O2 scavenging, DPPH, and FRAP assays. In-vivo studies employed adult male Wistar rats (200–250 g), divided into six groups (control, AlCl3-induced Alzheimer’s model, three cinchonidine dose groups at 10, 20, and 40 mg/kg, and a donepezil standard group). Treatments were administered orally for 21 days. Cognitive and behavioural assessments included the Elevated Plus Maze, T-maze, Y-maze, and locomotor activity via actophotometer. Post-treatment, hippocampus and cortex homogenates were analysed for acetylcholinesterase activity (Ellman’s method), catalase, lipid peroxidation (MDA via TBARS), and superoxide dismutase activities using spectrophotometric assays.ResultsMolecular docking revealed that cinchonidine binds acetylcholinesterase (AChE) with a −8.3 kcal/mol affinity, forming key hydrogen bonds and hydrophobic interactions, albeit weaker than donepezil (−11.3 kcal/mol). In-vitro assays demonstrated cinchonidine’s dose-dependent antioxidant activity comparable to ascorbic acid across H₂O₂ scavenging, DPPH, and FRAP assays. In-vivo, cinchonidine dose-dependently ameliorated AlCl₃-induced cognitive deficits, anxiety-like behaviour, and locomotor impairments in rats, paralleling donepezil effects. Biochemically, cinchonidine significantly restored brain AChE, lipid peroxidation, catalase, superoxide dismutase, and reduced glutathione levels (p < 0.05-0.001), indicating neuroprotective antioxidant and cholinergic modulation relevant to Alzheimer’s therapy.ConclusionCinchonidine demonstrated significant neuroprotective effects against AlCl3-induced cognitive dysfunction in rats through acetylcholinesterase inhibition and potent antioxidant activity. In-silico, in-vitro, and in-vivo results consistently showed dose-dependent improvements in cognitive behaviour, cholinergic function, and oxidative stress markers, comparable to donepezil. These findings highlight cinchonidine’s potential as a multifunctional therapeutic candidate for Alzheimer’s disease. Further studies exploring molecular mechanisms, long-term safety, and pharmacokinetics are warranted to advance its clinical translation.
- Open Access
- 25 April 2026
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 1081-1094
Evaluation of Potential Antidepressant Activity of Laserpitium Latifolium Plant: In Silico Molecular Docking, ADMET And In Vivo Analysis
Background: Globally, depression affects over 300 million people and is a leading cause of disability, yet current synthetic antidepressants often come with significant side effects such as weight gain, sexual dysfunction, and insomnia or suffer from a slow onset of action. This has driven a search for safer, plant-derived alternatives that can modulate the monoaminergic system (serotonin, norepinephrine, and dopamine) or target the neuro-inflammatory pathways. Aim: This study aims to investigate the antidepressant potential of an Ethanolic Extract of Laserpitium latifolium L (EELL). Methods: The plant material was extracted by maceration using ethanol as solvent. The obtained EELL was analysed by Gas Chromatography – Mass Spectrometry (GC-MS) to identify the active phytoconstituents. The selected phytoconstituents were selected as ligands, and human monoamine oxidase A (2Z5Y) was selected as the protein. Docking studies were performed, and finally, the extraction was used to perform in vivo antidepressant activity by using the Forced Swim Test (FST) and Tail Suspension method. Results: 29 compounds were identified through GC-MS analysis and in silico docking studies performed for 8 compounds using Monoamine Oxidase A (MAO-A; PDB ID: 2Z5Y) protein. out of 8 compounds, Blebbistatin exhibited superior binding affinity (-10.2 kcal/mol) compared to the standard MAO-A inhibitor, Imipramine (-8.0 kcal/mol). In the in vivo antidepressant study, 24 male Wistar albino rats were randomly divided into four groups: Group I (Normal control), Group II (Standard Imipramine, 10mg/kg), and Groups III and IV (Treatment groups, 200 and 400mg/kg, respectively). No morbidity and mortality were observed up to the dose of 2000 mg/kg. The antidepressant results showed that the extract significantly reduced immobility time in both the Forced Swim Test (FST) and Tail Suspension Test (TST) at doses of 200 and 400 mg/kg. Conclusion: The above findings suggest that L. latifolium L. exhibits antidepressant properties, supported by both in-silico and in vivo evidence. Major Findings: Laserpitium latifolium L. (EELL) demonstrated significant antidepressant-like effects in animal models, with the compound Blebbistatin showing higher binding affinity for MAO-A than the standard antidepressant Imipramine. Additionally, the extract exhibited a high safety profile, with no toxicity, morbidity, or mortality in rats at doses up to 2000 mg/kg, and GC-MS analysis identified 29 distinct bioactive compounds.
- 25 April 2026
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 1081-1094
Open AccessEvaluation of Potential Antidepressant Activity of Laserpitium Latifolium Plant: In Silico Molecular Docking, ADMET And In Vivo Analysis
Background: Globally, depression affects over 300 million people and is a leading cause of disability, yet current synthetic antidepressants often come with significant side effects such as weight gain, sexual dysfunction, and insomnia or suffer from a slow onset of action. This has driven a search for safer, plant-derived alternatives that can modulate the monoaminergic system (serotonin, norepinephrine, and dopamine) or target the neuro-inflammatory pathways. Aim: This study aims to investigate the antidepressant potential of an Ethanolic Extract of Laserpitium latifolium L (EELL). Methods: The plant material was extracted by maceration using ethanol as solvent. The obtained EELL was analysed by Gas Chromatography – Mass Spectrometry (GC-MS) to identify the active phytoconstituents. The selected phytoconstituents were selected as ligands, and human monoamine oxidase A (2Z5Y) was selected as the protein. Docking studies were performed, and finally, the extraction was used to perform in vivo antidepressant activity by using the Forced Swim Test (FST) and Tail Suspension method. Results: 29 compounds were identified through GC-MS analysis and in silico docking studies performed for 8 compounds using Monoamine Oxidase A (MAO-A; PDB ID: 2Z5Y) protein. out of 8 compounds, Blebbistatin exhibited superior binding affinity (-10.2 kcal/mol) compared to the standard MAO-A inhibitor, Imipramine (-8.0 kcal/mol). In the in vivo antidepressant study, 24 male Wistar albino rats were randomly divided into four groups: Group I (Normal control), Group II (Standard Imipramine, 10mg/kg), and Groups III and IV (Treatment groups, 200 and 400mg/kg, respectively). No morbidity and mortality were observed up to the dose of 2000 mg/kg. The antidepressant results showed that the extract significantly reduced immobility time in both the Forced Swim Test (FST) and Tail Suspension Test (TST) at doses of 200 and 400 mg/kg. Conclusion: The above findings suggest that L. latifolium L. exhibits antidepressant properties, supported by both in-silico and in vivo evidence. Major Findings: Laserpitium latifolium L. (EELL) demonstrated significant antidepressant-like effects in animal models, with the compound Blebbistatin showing higher binding affinity for MAO-A than the standard antidepressant Imipramine. Additionally, the extract exhibited a high safety profile, with no toxicity, morbidity, or mortality in rats at doses up to 2000 mg/kg, and GC-MS analysis identified 29 distinct bioactive compounds.
- Open Access
- 31 August 2025
- Published by Creative Pharma Assent in Journal of Applied Pharmaceutical Research
- Vol. 13 (4) , 162-176
In silico assessment of flavonoids from Matricaria chamomilla for anti-psoriatic potential via molecular docking and ADME/T profiling
Background: Computational tools are advancing in the drug discovery process to assess the safety profiles of new compounds with reduced investment. Herbal remedies exhibit a diverse range of active compounds that can alleviate various disease conditions with fewer side effects. Method: This study investigates the molecular docking of phytochemicals from Matricaria Chamomilla against inflammation-induced skin disorders, such as psoriasis. Using AutoDock Vina and MGL Tools, key compounds were evaluated for binding affinity with target proteins. ADMET analysis, as assessed by pkCSM and SWISSADME, to predict the Lipinski’s Rule of Five. Redocking was implemented to confirm the binding affinity of the docked position. Results: This molecular docking of phenolic compounds and flavonoids, including quercetin, apigenin, rutin, luteolin, and various glycosylated derivatives—from Matricaria Chamomilla against cellular proteins implicated in psoriasis (PDE-4, p38MAPK, IL-23, BTK, JAK-3, TNF-α, IL-17A, and IL-6). Using Autodock Vina and MGL Tools, rutin and quercetin demonstrated favourable binding affinities. At the same time, luteolin-7-glycoside exhibited the highest docking scores (e.g., -10.8 kcal/mol for PDE-4, -9.7 kcal/mol for JAK-3, and -9.1 kcal/mol for TNF-α) compared to the standard. Results highlight the potential of chamomile phytochemicals as safe, orally effective agents for managing inflammatory skin conditions. Redocking confirms the RMSD values are within the limits of < 2 A0. Conclusion: The data suggest that chamomile flavonoids could be safe and beneficial for treating inflammatory diseases and psoriasis. Although enzymatic and cell-based assays, along with further preclinical evaluations, are essential for advancing research in disease modification, formulation strategies play a role in improving drug characteristics
- 31 August 2025
- Published by Creative Pharma Assent in Journal of Applied Pharmaceutical Research
- Vol. 13 (4) , 162-176
Open AccessIn silico assessment of flavonoids from Matricaria chamomilla for anti-psoriatic potential via molecular docking and ADME/T profiling
Background: Computational tools are advancing in the drug discovery process to assess the safety profiles of new compounds with reduced investment. Herbal remedies exhibit a diverse range of active compounds that can alleviate various disease conditions with fewer side effects. Method: This study investigates the molecular docking of phytochemicals from Matricaria Chamomilla against inflammation-induced skin disorders, such as psoriasis. Using AutoDock Vina and MGL Tools, key compounds were evaluated for binding affinity with target proteins. ADMET analysis, as assessed by pkCSM and SWISSADME, to predict the Lipinski’s Rule of Five. Redocking was implemented to confirm the binding affinity of the docked position. Results: This molecular docking of phenolic compounds and flavonoids, including quercetin, apigenin, rutin, luteolin, and various glycosylated derivatives—from Matricaria Chamomilla against cellular proteins implicated in psoriasis (PDE-4, p38MAPK, IL-23, BTK, JAK-3, TNF-α, IL-17A, and IL-6). Using Autodock Vina and MGL Tools, rutin and quercetin demonstrated favourable binding affinities. At the same time, luteolin-7-glycoside exhibited the highest docking scores (e.g., -10.8 kcal/mol for PDE-4, -9.7 kcal/mol for JAK-3, and -9.1 kcal/mol for TNF-α) compared to the standard. Results highlight the potential of chamomile phytochemicals as safe, orally effective agents for managing inflammatory skin conditions. Redocking confirms the RMSD values are within the limits of < 2 A0. Conclusion: The data suggest that chamomile flavonoids could be safe and beneficial for treating inflammatory diseases and psoriasis. Although enzymatic and cell-based assays, along with further preclinical evaluations, are essential for advancing research in disease modification, formulation strategies play a role in improving drug characteristics
- 30 June 2025
- Published by GSC Online Press in World Journal of Biology Pharmacy and Health Sciences
- Vol. 22 (3) , 427-434
Strategic improvement of bioavailability in flavonoids by using non - oral routes
Flavonoids are polyphenolic chemicals that exist naturally and are well known for their strong anti-inflammatory, anti-oxidant, and medicinal properties. However, significant first-pass hepatic metabolism, enzymatic breakdown in the gastrointestinal system, and poor oral bioavailability resulting from low water solubility frequently restrict their clinical usefulness. Transdermal, intranasal, buccal, pulmonary, and rectal drug delivery methods have become viable substitutes to get around these restrictions. These pathways improve systemic absorption and therapeutic efficacy by avoiding hepatic metabolism and gastrointestinal breakdown. More sophisticated drug delivery methods, such as liposomes, microneedles, nanocarriers, and mucoadhesive formulations, help to enhance the permeability, sustained release, and targeted administration of flavonoids. The strategic use of non-oral methods and innovative formulations to improve flavonoid bioavailability is highlighted in this article, opening the door to more efficient and patient-friendly treatment alternatives.
- 30 June 2025
- Published by GSC Online Press in World Journal of Biology Pharmacy and Health Sciences
- Vol. 22 (3) , 427-434
Strategic improvement of bioavailability in flavonoids by using non - oral routes
Flavonoids are polyphenolic chemicals that exist naturally and are well known for their strong anti-inflammatory, anti-oxidant, and medicinal properties. However, significant first-pass hepatic metabolism, enzymatic breakdown in the gastrointestinal system, and poor oral bioavailability resulting from low water solubility frequently restrict their clinical usefulness. Transdermal, intranasal, buccal, pulmonary, and rectal drug delivery methods have become viable substitutes to get around these restrictions. These pathways improve systemic absorption and therapeutic efficacy by avoiding hepatic metabolism and gastrointestinal breakdown. More sophisticated drug delivery methods, such as liposomes, microneedles, nanocarriers, and mucoadhesive formulations, help to enhance the permeability, sustained release, and targeted administration of flavonoids. The strategic use of non-oral methods and innovative formulations to improve flavonoid bioavailability is highlighted in this article, opening the door to more efficient and patient-friendly treatment alternatives.
- Open Access
- 23 April 2025
- Published by Manuscript Technomedia LLP in International Journal of Pharmaceutical Investigation
- Vol. 15 (3) , 770-776
Targeted Lipid Based Vesicles as Drug Delivery Systems in Cancer Treatment
Cancer is not a single disease, it is a multifaced malignant tumor, having ability to develop in any part of our body and it can spread to the distant regions with the high-end cell proliferation within short duration of time. As per WHO statistics in 2023, 1 in 6 deaths occurred globally caused by cancer. Out of the available treatments to treat cancer like surgery, radiotherapy, chemotherapy, stem cell, targeted drug therapy, most promising and lifelong treatment continued by the chemotherapy agents. These drugs continuous usage may leads to the Multi Drug Resistance (MDR) and toxic effects. Application of nano therapeutical treatment with lipid vesicular systems may provide the less toxic effects, increased permeation into tumor cells, avoid the MDR effect. Lipid vesicular systems like liposomes, ethosomes and transferosomes are some of the leading drug delivery systems. Modification on the surface of the lipid layer can change the drug pharmacokinetic properties to achieve the maximum bioavailability and reduce the risk of toxicity. Plant based drugs delivery through the lipid vesicles is the majorly concerned to benefit the cancer patient with the improved nutritional support and less toxic nature of chemical compounds.
- 23 April 2025
- Published by Manuscript Technomedia LLP in International Journal of Pharmaceutical Investigation
- Vol. 15 (3) , 770-776
Open AccessTargeted Lipid Based Vesicles as Drug Delivery Systems in Cancer Treatment
Cancer is not a single disease, it is a multifaced malignant tumor, having ability to develop in any part of our body and it can spread to the distant regions with the high-end cell proliferation within short duration of time. As per WHO statistics in 2023, 1 in 6 deaths occurred globally caused by cancer. Out of the available treatments to treat cancer like surgery, radiotherapy, chemotherapy, stem cell, targeted drug therapy, most promising and lifelong treatment continued by the chemotherapy agents. These drugs continuous usage may leads to the Multi Drug Resistance (MDR) and toxic effects. Application of nano therapeutical treatment with lipid vesicular systems may provide the less toxic effects, increased permeation into tumor cells, avoid the MDR effect. Lipid vesicular systems like liposomes, ethosomes and transferosomes are some of the leading drug delivery systems. Modification on the surface of the lipid layer can change the drug pharmacokinetic properties to achieve the maximum bioavailability and reduce the risk of toxicity. Plant based drugs delivery through the lipid vesicles is the majorly concerned to benefit the cancer patient with the improved nutritional support and less toxic nature of chemical compounds.
- Open Access
- 7 March 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 402-414
QBD APPROACH FOR THE DEVELOPMENT OF NANOSPONGE LOADED TOPICAL GEL OF FUCOIDAN FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: IN VITRO, EX-VIVO, AND IN VIVO ASSESSMENT
Objective: This contemporary research reports the fabrication, optimization, and evaluation of Fucoidan (FDN)-loaded Nanosponges (NS) based gel for the treatment of rheumatoid arthritis. Methods: Risk assessment was performed, followed by screening and optimization of NS formulation by 32 factorial design using Design-Expert® software. FDN-loaded NS prepared by emulsion solvent evaporation technique was subjected to different solid and liquid state characterizations and subsequently loaded in carbopol gel. The effects of pro-inflammatory cytokines (IL-1 and TNFα) were evaluated using macrophage cells. Results: The physical and chemical characteristics exhibited by the prepared NS and gels (F1-F9) were found to be optimal. The optimization resulted in achieving formulation NS1 with 72.6% in vitro drug release and 8457cp viscosity and followed the Higuchi-matrix model. Histopathology studies revealed that prepared nanogel has promising anti-arthritic activity. The skin permeation studies showed that the optimized gel formulation was successful in stopping the drug from permeation through the skin. Moreover, the nanogel has depicted sustained drug release till 24 h. Conclusion: Hence, the NS-based the delivery system developed and assessed in the current research approach seemed to be auspicious concerning preventing rheumatoid arthritis along with practical utilization in the pharmaceutical field.
- 7 March 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 402-414
Open AccessQBD APPROACH FOR THE DEVELOPMENT OF NANOSPONGE LOADED TOPICAL GEL OF FUCOIDAN FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: IN VITRO, EX-VIVO, AND IN VIVO ASSESSMENT
Objective: This contemporary research reports the fabrication, optimization, and evaluation of Fucoidan (FDN)-loaded Nanosponges (NS) based gel for the treatment of rheumatoid arthritis. Methods: Risk assessment was performed, followed by screening and optimization of NS formulation by 32 factorial design using Design-Expert® software. FDN-loaded NS prepared by emulsion solvent evaporation technique was subjected to different solid and liquid state characterizations and subsequently loaded in carbopol gel. The effects of pro-inflammatory cytokines (IL-1 and TNFα) were evaluated using macrophage cells. Results: The physical and chemical characteristics exhibited by the prepared NS and gels (F1-F9) were found to be optimal. The optimization resulted in achieving formulation NS1 with 72.6% in vitro drug release and 8457cp viscosity and followed the Higuchi-matrix model. Histopathology studies revealed that prepared nanogel has promising anti-arthritic activity. The skin permeation studies showed that the optimized gel formulation was successful in stopping the drug from permeation through the skin. Moreover, the nanogel has depicted sustained drug release till 24 h. Conclusion: Hence, the NS-based the delivery system developed and assessed in the current research approach seemed to be auspicious concerning preventing rheumatoid arthritis along with practical utilization in the pharmaceutical field.
- Open Access
- 28 February 2025
- Published by Creative Pharma Assent in Journal of Applied Pharmaceutical Research
- Vol. 13 (1) , 95-111
Insilico molecular docking and ADME/T studies of flavonol compounds against selected proteins involved in inflammation mechanism
Background: Using computational tools in drug discovery advanced the research in identifying new drug candidates for the benefit of the pharmaceutical industry and assessing the safety and pharmacokinetic profiles of phytochemicals. Understanding the inflammatory mechanism is not possible, but inflammatory signal transduction by cytokines can be mitigated by using the flavonoid class of drugs like flavonols. Methodology: A molecular docking study of flavonol compounds with proteins linked with inflammation was carried out using the AutodockVina program. SwissADME and pkCSM modules were used to assess the pharmacokinetic features of plant products. Compared to commercially available NSAIDs, flavonols had more excellent molecular docking scores. Results: Calculation of ADME features of flavonols with no carcinogenicity and low oral acute toxicity level. Compared to anti-inflammatory medicines, the Rutin docking score against COX-I (-8.7 kcal/mol) and the Galangin docking score against COX-II enzymes (-9.4 kcal/mol) had higher values. Discussion: Molecular docking studies exhibited the highest docking score for COX-I is Rutin -8.7 Kcal/mol and hydrogen bond with THR-89, PRO-84, LS-468, GLY-471, PHE-470. The highest docking for COX-II is Galangin -9.4 Kcal/mol and hydrogen bonding with VAL-349 and TYR-385. ADME/T studies were performed for all the flavonols. Rutin has the highest violations in drug-likeliness studies. Conclusion: Flavonols may be more effective anti-inflammatory medicines than commercial medications. By modifying the pharmacokinetic features of plant products through diverse formulation strategies, we can get these phytochemicals to their target sites with fewer adverse effects.
- 28 February 2025
- Published by Creative Pharma Assent in Journal of Applied Pharmaceutical Research
- Vol. 13 (1) , 95-111
Open AccessInsilico molecular docking and ADME/T studies of flavonol compounds against selected proteins involved in inflammation mechanism
Background: Using computational tools in drug discovery advanced the research in identifying new drug candidates for the benefit of the pharmaceutical industry and assessing the safety and pharmacokinetic profiles of phytochemicals. Understanding the inflammatory mechanism is not possible, but inflammatory signal transduction by cytokines can be mitigated by using the flavonoid class of drugs like flavonols. Methodology: A molecular docking study of flavonol compounds with proteins linked with inflammation was carried out using the AutodockVina program. SwissADME and pkCSM modules were used to assess the pharmacokinetic features of plant products. Compared to commercially available NSAIDs, flavonols had more excellent molecular docking scores. Results: Calculation of ADME features of flavonols with no carcinogenicity and low oral acute toxicity level. Compared to anti-inflammatory medicines, the Rutin docking score against COX-I (-8.7 kcal/mol) and the Galangin docking score against COX-II enzymes (-9.4 kcal/mol) had higher values. Discussion: Molecular docking studies exhibited the highest docking score for COX-I is Rutin -8.7 Kcal/mol and hydrogen bond with THR-89, PRO-84, LS-468, GLY-471, PHE-470. The highest docking for COX-II is Galangin -9.4 Kcal/mol and hydrogen bonding with VAL-349 and TYR-385. ADME/T studies were performed for all the flavonols. Rutin has the highest violations in drug-likeliness studies. Conclusion: Flavonols may be more effective anti-inflammatory medicines than commercial medications. By modifying the pharmacokinetic features of plant products through diverse formulation strategies, we can get these phytochemicals to their target sites with fewer adverse effects.
- Open Access
- 7 June 2024
- Published by Innovare Academic Sciences Pvt Ltd in Asian Journal of Pharmaceutical and Clinical Research
- p. 9-17
FLAVANOIDS: AN ERA OF NUTRACEUTICALS TURNING IN TO MEDICINAL AGENTS
Flavonoids, present in plants, constitute a varied group of naturally occurring compounds well-known for their potential positive effects on health. These molecules present in fruits, vegetables, and beverages such as tea exhibit antioxidant, anti-inflammatory, and other bioactive properties that contribute to their positive impact on human health. In addition, flavonoids act as antioxidants, helping plants combat oxidative stress. Some flavonoids also participate in ultraviolet protection, defense against pathogens, and modulation of plant-microbe interactions. Flavonoids have a different subclass of flavones, flavonols, flavanones, flavan-3-ols, anthocyanins, and isoflavones. The term “bioavailability” describes how well the body absorbs and uses flavonoids, a broad class of plant-based chemicals. The chemical structure of flavonoids, the matrix of foods they are eaten interactions with other dietary components influence their bioavailability. This metabolism can lead to the formation of various metabolites, impacting the compounds’ bioactivity. Understanding these aspects is crucial for unlocking the full potential of flavonoids in promoting health and preventing diseases. Patents on flavonoids serve as legal protections for innovations related to these plant compounds. Companies and researchers seek patents to safeguard novel methods of extraction, synthesis, and applications ensuring exclusivity for a specified period. This exclusivity incentivizes investment in research and development, promoting the exploration of flavonoids for pharmaceuticals, food additives, and cosmetics. Ultimately, these legal protections encourage advancements in understanding and harnessing the diverse benefits of flavonoids across various industries.
- 7 June 2024
- Published by Innovare Academic Sciences Pvt Ltd in Asian Journal of Pharmaceutical and Clinical Research
- p. 9-17
Open AccessFLAVANOIDS: AN ERA OF NUTRACEUTICALS TURNING IN TO MEDICINAL AGENTS
Flavonoids, present in plants, constitute a varied group of naturally occurring compounds well-known for their potential positive effects on health. These molecules present in fruits, vegetables, and beverages such as tea exhibit antioxidant, anti-inflammatory, and other bioactive properties that contribute to their positive impact on human health. In addition, flavonoids act as antioxidants, helping plants combat oxidative stress. Some flavonoids also participate in ultraviolet protection, defense against pathogens, and modulation of plant-microbe interactions. Flavonoids have a different subclass of flavones, flavonols, flavanones, flavan-3-ols, anthocyanins, and isoflavones. The term “bioavailability” describes how well the body absorbs and uses flavonoids, a broad class of plant-based chemicals. The chemical structure of flavonoids, the matrix of foods they are eaten interactions with other dietary components influence their bioavailability. This metabolism can lead to the formation of various metabolites, impacting the compounds’ bioactivity. Understanding these aspects is crucial for unlocking the full potential of flavonoids in promoting health and preventing diseases. Patents on flavonoids serve as legal protections for innovations related to these plant compounds. Companies and researchers seek patents to safeguard novel methods of extraction, synthesis, and applications ensuring exclusivity for a specified period. This exclusivity incentivizes investment in research and development, promoting the exploration of flavonoids for pharmaceuticals, food additives, and cosmetics. Ultimately, these legal protections encourage advancements in understanding and harnessing the diverse benefits of flavonoids across various industries.
- 6 February 2024
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 107 (3) , 377-386
QbD-Based Stability-Indicating RP-HPLC Method Development and Validation for the Estimation of Favipiravir—An Eco-Friendly Approach
Background: Analytical quality by design (AQbD) affords a systematic scaffolding to triumph a continuously validated, robust assay as well as life cycle management. The resuscitative repurposed drug favipiravir, an oral drug approved for reemerging pandemic influenza in Japan in 2014, is used for the treatment of life-threatening pathogens such as Ebola, Lassa virus, and currently COVID-19. Favipiravir is gaining a great deal of medical importance due to its pharmaceutical applications. Objective: To develop and validate a risk-based stability-indicating RP-HPLC method employing an AQbD approach using Central Composite Design (Design Expert Software 13.0) for the estimation of favipiravir. Method: The Quality Target Product Profile optimized were flow rate and mobile phase composition, thus assessing the critical analytical attributes (retention time, tailing factor, and number of theoretical plates) as the constraints of method robustness. The proposed technique was optimized with a C18 (150 × 4.6 mm, 5 µm) column and 0.1% orthophosphoric acid buffer–acetonitrile (50:50, v/v) as the mobile phase at a flow rate of 1 mL/min using diode-array detector (230 nm) eluted favipiravir at 2.3 min. Results: The optimized method validated as per ICH guideline Q2 (R1) was found to be eco-friendly, simple, precise (RSD 0.0051–1.2%), accurate (99.86–100.22%), linear (25–150 µg/mL), rugged (RSD 0.70%), and robust (RSD 0.6–1.6%) with a limit of detection and limit of quantitation of 1.140 µg/mL and 4.424 µg/mL, respectively. Conclusion: Forced degradation studies (acidic, alkaline, thermal, photolytic, and oxidative conditions) revealed the suitability of the AQbD method for the analysis of favipiravir in tablet formulation.The developed and validated AQbD method is less time consuming and can be used in the industry for routine quality control/analysis of bulk drug and marketed Favipiravir products. Highlights: A robust Design of Experiment enhanced stability-indicating analytical method was developed and validated for the estimation of favipiravir. Furthermore, the contemporary method would aid in extending the analysis of favipiravir in other formulations.
- 6 February 2024
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 107 (3) , 377-386
QbD-Based Stability-Indicating RP-HPLC Method Development and Validation for the Estimation of Favipiravir—An Eco-Friendly Approach
Background: Analytical quality by design (AQbD) affords a systematic scaffolding to triumph a continuously validated, robust assay as well as life cycle management. The resuscitative repurposed drug favipiravir, an oral drug approved for reemerging pandemic influenza in Japan in 2014, is used for the treatment of life-threatening pathogens such as Ebola, Lassa virus, and currently COVID-19. Favipiravir is gaining a great deal of medical importance due to its pharmaceutical applications. Objective: To develop and validate a risk-based stability-indicating RP-HPLC method employing an AQbD approach using Central Composite Design (Design Expert Software 13.0) for the estimation of favipiravir. Method: The Quality Target Product Profile optimized were flow rate and mobile phase composition, thus assessing the critical analytical attributes (retention time, tailing factor, and number of theoretical plates) as the constraints of method robustness. The proposed technique was optimized with a C18 (150 × 4.6 mm, 5 µm) column and 0.1% orthophosphoric acid buffer–acetonitrile (50:50, v/v) as the mobile phase at a flow rate of 1 mL/min using diode-array detector (230 nm) eluted favipiravir at 2.3 min. Results: The optimized method validated as per ICH guideline Q2 (R1) was found to be eco-friendly, simple, precise (RSD 0.0051–1.2%), accurate (99.86–100.22%), linear (25–150 µg/mL), rugged (RSD 0.70%), and robust (RSD 0.6–1.6%) with a limit of detection and limit of quantitation of 1.140 µg/mL and 4.424 µg/mL, respectively. Conclusion: Forced degradation studies (acidic, alkaline, thermal, photolytic, and oxidative conditions) revealed the suitability of the AQbD method for the analysis of favipiravir in tablet formulation.The developed and validated AQbD method is less time consuming and can be used in the industry for routine quality control/analysis of bulk drug and marketed Favipiravir products. Highlights: A robust Design of Experiment enhanced stability-indicating analytical method was developed and validated for the estimation of favipiravir. Furthermore, the contemporary method would aid in extending the analysis of favipiravir in other formulations.